Phase I Study of WTX212A Injection Alone or With Radiotherapy for Patients With Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating the preliminary effects, safety, immune response, and how the body processes a drug called WTX212A Injection in adults with advanced solid tumors. This single-arm, open-label study includes patients with confirmed advanced malignant tumors and aims to understand how WTX212A works alone or combined with radiotherapy. The study is investigator-initiated and focuses on early-phase results to guide future research. The study has two groups one receiving only WTX212A and another receiving WTX212A along with radiotherapy. Radiotherapy is given first, followed by WTX212A starting within a week after radiotherapy ends. The study includes an initial exploratory phase and then an expansion phase to further assess treatments. Participants receive the study drug and may undergo radiotherapy as part of their treatment. Participants will be followed for about one year on average, with regular assessments every six weeks during treatment. Researchers will monitor how well the treatments work, measure safety and side effects, and study the drugs behavior in the body, including immune responses. The study includes laboratory tests and clinical evaluations to gather detailed information throughout the treatment and follow-up periods.

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors